Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

IPHA Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Innate Pharma S.A.NASDAQ: IPHA

Net Change in Cash · Q4 FY2025 · quarter ended Dec 2025

Net change in cash grows 611.6% year over year

Q4 FY2025 net change in cash of €25.57M (cash outflow) rose 611.6% year over year. Over 3 fiscal years it compounded at +15.9% a year.

Context

  • Net change in cash amounted to 1092.1% of revenue in FY2025, up 1058.7 pp from a year earlier.
  • Net change in cash grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-€25.57M— QoQ
Last fiscal yearDec 2025
-€30.44M+623.1% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+611.6%——
1 year+623.1%——
3-year CAGR+15.9%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

EUR · from the cash flow

Latest · FY2025
(30.44M) EUR
Year-over-year change
-623.1%

Net Change in Cash vs competitors

How IPHA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +623.1% is the highest of 8, against a peer median of -145.5%.
  • Net change in cash amounts to 1092.1% of revenue for IPHA, versus a peer median of 784.9%.
IPHA Competitors
Net Change in Cash for IPHA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGENCompugen Ltd.LTM Dec 2025$72.37M USD—+192.0%99.5%
MOLNMolecular Partners AGLTM Mar 2026CHF 41.33M CHF-462.5%+5.2%—
IPHAInnate Pharma S.A.FY2025€30.44M EUR+623.1%+15.9%1092.1%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$26.23M USD-25.0%—1470.4%
CRDFCardiff Oncology, Inc.LTM Mar 2026$15.55M USD-386.0%—2962.1%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$6.48M USD+35.0%——
NVCTNuvectis Pharma, Inc.LTM Mar 2026$4.73M USD-145.5%-2.8%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$4.08M USD-162.5%-47.7%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$767K USD-123.7%—24.2%
Peer median (excluding IPHA) —-145.5%+1.2%784.9%

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
Deferred Income Tax(1.68M)0000
Stock-Based Compensation2.62M4.25M4.26M3.94M4.26M
Change in Working Capital(9.88M)(12.5M)(32.09M)39.16M(10.21M)
Accounts Receivables3.39M(4.2M)(13.67M)00
Inventory(6.27M)0000
Accounts Payables(946K)(7.66M)(3.89M)00
Other Working Capital(6.06M)(636K)(10.54M)39.16M(10.21M)
Other Non-Cash Items(1.3M)1.8M(2.24M)(2.53M)(630.52K)
Operating Cash Flow(58.46M)(19.15M)(32.56M)(6.9M)(50.67M)
Capital Expenditures(1.33M)(1.12M)(2.35M)(391K)(134.47K)
Acquisitions (Net)7K0004.8K
Purchases of Investments00000
Sales of Investments03M22.77M9.59M13.51M
Other Investing Activities406K(1K)(1.79M)1K(6.38M)
Investing Cash Flow(917K)1.88M20.63M9.2M7M
Debt Repayment26.63M(2.03M)(2.36M)(8.94M)(8.56M)
Common Stock Issued499K198K395K2.93M14.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities187K198K395K2.93M0
Financing Cash Flow26.82M(1.83M)(1.97M)(6.01M)5.83M
Effect of Forex Changes(483K)(428K)274K(505K)7.41M
Net Change in Cash(33.04M)(19.53M)(13.62M)(4.21M)(30.44M)
Free Cash Flow(59.79M)(20.28M)(34.91M)(7.29M)(50.81M)

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.